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from the intestine and not with feline infectious
peritonitis
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Abstract
Recent evidence suggests that a mutation in the spike protein gene of feline coronavirus (FCoV), which results in an
amino acid change from methionine to leucine at position 1058, may be associated with feline infectious peritonitis
(FIP). Tissue and faecal samples collected post mortem from cats diagnosed with or without FIP were subjected to RNA
extraction and quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) to detect FCoV RNA. In cats with
FIP, 95% of tissue, and 81% of faecal samples were PCR-positive, as opposed to 22% of tissue, and 60% of faecal
samples in cats without FIP. Relative FCoV copy numbers were significantly higher in the cats with FIP, both in
tissues (P < 0.001) and faeces (P = 0.02). PCR-positive samples underwent pyrosequencing encompassing position
1058 of the FCoV spike protein. This identified a methionine codon at position 1058, consistent with the shedding
of an enteric form of FCoV, in 77% of the faecal samples from cats with FIP, and in 100% of the samples from cats
without FIP. In contrast, 91% of the tissue samples from cats with FIP and 89% from cats without FIP had a leucine
codon at position 1058, consistent with a systemic form of FCoV. These results suggest that the methionine to leucine
substitution at position 1058 in the FCoV spike protein is indicative of systemic spread of FCoV from the intestine, rather
than a virus with the potential to cause FIP.
Introduction
Feline coronavirus (FCoV) infection is ubiquitous in do-
mestic cats, particularly in multi-cat households where up
to 90% of animals may be infected [1-3]. The majority of
FCoV infections are asymptomatic or are associated with
mild enteric disease [4]. However, approximately 5-12% of
infected cats develop the invariably fatal disease, feline
infectious peritonitis (FIP) [5-7].
One of the most important questions in FCoV research
is why some FCoV-infected cats develop FIP, whereas
others remain healthy. One current model of FIP patho-
genesis proposes that cats are infected with FCoV by the
faecal-oral route. Subsequently, the virus mutates into
the virulent form. This form has an enhanced tropism
for monocytes/macrophages, and in vitro studies suggest
that this is reflected as sustainable replication in, and
subsequent activation of, monocytes [8,9]. These activated
monocytes carry the virus in the blood and, as a result of
complex interactions with endothelial cells, induce the
granulomatous phlebitis that is the pathogenic hallmark of
FIP [10,11]. The age, breed, gender, reproductive status
and immune response of individual cats also influence the
development of FIP [12].
Currently, there is intense interest in determining
which mutations alter the virulence of FCoVs. A recent
paper published by Chang et al. [13] derived full genome
sequence data from a collection of FCoVs obtained from
the faeces of healthy cats and from the tissues of cats
diagnosed with FIP. They provided evidence of an
association between FCoV virulence and an amino acid
substitution (methionine to leucine at position 1058,
M1058L) within the putative fusion peptide of the FCoV
spike (S) protein. Specifically, the authors concluded that
the M1058L substitution distinguished FIP from non-FIP
associated FCoVs in 92% of cases. A second substitution,
* Correspondence: Stuart.Siddell@bristol.ac.uk
1School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8
1TD, UK
Full list of author information is available at the end of the article
VETERINARY RESEARCH
© 2014 Porter et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Porter et al. Veterinary Research 2014, 45:49
http://www.veterinaryresearch.org/content/45/1/49
two amino acids downstream of M1058L (serine to alanine
at position 1060, S1060A) distinguished a further 4% of
FIP from non-FIP associated FCoVs. The S protein fusion
peptide is a critical element in the fusion of viral and
cellular membranes during virus entry [14] and it is
reasonable to think that amino acid substitutions within
this peptide may alter the tropism of the virus.
In addition, a study by Licitra et al. has shown that it is
possible to distinguish between FCoVs from animals with
and without FIP on the basis of one or more substitutions
in the amino acid sequence that comprises the furin
cleavage motif within the S protein [15]. This furin
cleavage site (consensus motif R-X-K/R-R, where R is
the basic arginine residue, X is any residue and K is
the basic lysine residue) delineates the border of the
receptor-binding (S1) and fusion (S2) domains of the S
protein and is distinct to the M1058L substitution site
described above. Mutation at this site is proposed to
alter proteolytic cleavage of the S protein and modify
S protein fusogenic properties, which again may relate
to the tropism of the virus [15].
Finally, Pedersen et al. [16] concluded that truncating
and non-truncating mutations in the 3c gene occur in a
significant proportion of FCoVs associated with FIP.
Chang et al. [17] suggest that functional 3c protein
expression is crucial for FCoV replication in the gut
but is dispensable for systemic replication. However,
they also do not exclude the possibility that the loss or
alteration of the 3c protein may enhance the fitness of
the virus in the monocyte/macrophage environment.
Over the past 8 years, the University of Bristol has col-
lected a large number of post-mortem tissue and faecal
samples from a cohort of thoroughly examined cats. These
include cats with a definite diagnosis of FIP, confirmed by
the presence of the typical histological FIP lesions, in
which immunohistochemistry (IHC) demonstrated FCoV
antigen within macrophages [18], and cats with diseases
other than FIP that completely lacked any histological
changes consistent with FIP. Importantly, this long-term
study has enabled both faecal and tissue samples to be
collected from FCoV-infected cats with and without FIP,
allowing comparable samples from naturally infected cats
to be examined. Samples were screened for FCoV RNA
by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR) [19] and, if positive, were assessed
for the M1058L substitution by pyrosequencing.
Materials and methods
Sample collection and storage
Post-mortem tissue samples, and faeces whenever pos-
sible, were collected from cats that were euthanized with
suspected FIP, or due to other diseases. FIP was then
definitively diagnosed or excluded by histopathology and,
in the case of FIP, the demonstration of FCoV antigen in
FIP lesions by IHC [18]. Tissues of cats without FIP were
also tested by IHC for the presence of viral antigen.
Tissue samples were collected into RNAlater (Life
Technologies) within 2 h of death for subsequent molecu-
lar analysis. The tissue samples were left in RNAlater for
24-48 h at room temperature or 4 °C before the RNAlater
was discarded, and the tissue samples stored at −80 °C.
The faecal samples were stored at −80 °C until use. Fur-
ther samples were collected into 10% neutral-buffered
formalin for histology and IHC. The tissues collected
comprised primarily mesenteric lymph node, liver, kidney,
spleen and omentum, while other tissues (e.g. intestine,
brain, lung, pericardium, pancreas or other lymph nodes)
were included based on gross pathological findings or
reported clinical signs.
Histology and IHC for FCoV antigen
The formalin-fixed tissue samples were subjected to stand-
ard processing for histopathology. They were embedded
in paraffin wax and sections prepared and stained by
haematoxylin-eosin. Sections were examined by a board-
certified veterinary pathologist (MJD) at the University
of Bristol for histopathological changes. Selected wax
blocks were then sent to Veterinary Laboratory Services,
University of Liverpool for IHC analysis as previously
described [18]. For a cat to be assigned to the “FIP group”,
it needed to have histopathological changes consistent
with FIP in which FCoV antigen was demonstrated within
macrophages in lesions [18]. For a cat to be assigned to
the “non-FIP group”, histopathological changes consistent
with FIP needed to be completely absent, and FCoV
antigen within macrophages needed to be absent for all
tissues. Only individual tissue samples with a positive
qRT-PCR result, and lesions consistent with FIP on histo-
pathology were used for pyrosequencing. Faecal samples
were classified on the basis of the diagnosis attributed to
the cat from which the sample originated.
RNA extraction and qRT-PCR
Total RNA was extracted from 20 mg of tissue or 10 mg
of faeces with a NucleoSpin RNA II kit (Macherey-Nagel)
using methods based on previous work by Dye and Siddell
[19,20]. Reverse transcription was done using a MJ Mini
Gradient Thermal Cycler and ImProm II Reverse Tran-
scriptase (Promega). Nine microlitres of total RNA solu-
tion were combined with 4 μL ImProm II 5× Reaction
Buffer, 2.4 μL 25 mM MgCl2, 1 μL dNTPs (10 mM each),
1 μL random hexamers (0.5 μg/μL) and 1 μL ImProm II
reverse transcriptase. The reaction was made up to a total
volume of 20 μL with RNase-free water. The following
thermal profile was used; 20 °C for 5 min, 42 °C for
30 min, 70 °C for 15 min and 4 °C hold. The resulting
20 μL of cDNA was added to 30 μL of RNase-free water
and stored at −20 °C. Randomly selected samples were
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checked for inhibition of the RT reaction using an RNA
internal amplification control. No inhibition was detected
(results not shown).
The qPCR was done on an Agilent Mx3005P qPCR
System (Agilent Technologies). A qPCR master mix was
made for each reaction with 12.5 μL 2× GoTaq Master
Mix (Promega), 0.5 μL of 10 μM forward and reverse
primer (P009/P010) (Table 1), 0.125 μL of 5 μM Taqman
probe (Table 1), 1.25 μL 50 mM MgCl2 and made up to
20 μL with RNase-free water. The primers and probe
were produced by Metabion (Metabion International)
and were described previously by Dye et al. [19].
One-tenth of the randomly primed cDNA (5 μL) was
added to the PCR master mix. The reaction plate was
heat sealed and the following thermal profile was used:
95 °C for 2 min, 40 cycles of 95 °C for 15 s, 55 °C for
15 s and 72 °C for 15 s. Fluorescence was detected at
520 nm during the extension phase. Feline CoV cDNA
was used as a positive control and RNase-free water as a
negative control.
Reactions that failed to reach the threshold cycle (Ct)
value by cycle 40 were deemed to be negative. A Ct
value of 40 was assigned a relative copy number of 1
[21,22], and the following equation, which takes into
account the 96% efficiency of the qRT-PCR assay [19],
was used to calculate the relative copy number of each
qRT-PCR positive sample: 1.96 (40-Ct value).
Pyrosequencing
All samples that were positive by FCoV qRT-PCR under-
went conventional PCR to amplify a 153 base-pair DNA
fragment encompassing position 1058 in the S protein
gene. PCR was done using a MJ Mini Gradient Thermal
Cycler. Briefly, for each reaction, a PCR mix was made
that included 12.5 μL 2× GoTaq Master Mix, 0.5 μL of
10 μM forward and reverse primer (F614/R766) (Table 1),
2 μL of randomly primed cDNA reaction products and
water to a volume of 25 μL. The following thermal profile
was used; 95 °C for 2 min, 40 cycles of 95 °C for 15 s, 52 °C
for 20 s and 72 °C for 20 s, before being held at 4 °C. The
PCR products were used for the pyrosequencing reaction
or stored at -20 °C until required. Samples that failed to
produce definitive sequence data were pyrosequenced,
following repeat amplification using the same PCR proto-
col with 50 cycles of amplification.
Single strand sequencing templates were produced by
binding the biotinylated PCR product to streptavidin-
coated Sepharose beads (Fisher), followed by chemical
denaturation and neutralisation. For each sample, the
following mix was prepared; 2 μL streptavidin beads,
40 μL PyroMark binding buffer (Qiagen) (pH 7.6 con-
taining 10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.1%
Tween 20) made up to 55 μL with water. The bead
mixture was added to the PCR product and shaken at
1400 rpm for 10 min. The sequencing primer mix con-
tained 0.75 μL 10 μM sequencing primer (Table 1) and
24.25 μL PyroMark annealing buffer (Qiagen) (20 mM
Tris-OAc, 5 mM Mg-OAc pH 7.6) for each sample. The
control oligonucleotide (a self-sequencing oligonucleotide)
mix contained 1 μL 10 μM oligonucleotide C4 and 24 μL
annealing buffer. Twenty five microlitres of the sequen-
cing primer mix was added to the appropriate wells of a
pyrosequencing plate, 25 μL of control oligonucleotide
was added to one well, and the plate was placed on the
pyrosequencing workstation.
Table 1 Primer and probe sequences used in this study
Name Use Sequence (5’- 3’) Position in FCoV
(strain 79-11461) genome
Position in FCoV
(strain C1Je2) genome
P009 qPCR forward primer AGCAACTACTGCCACRGGAT 26655..26674
P010 qPCR reverse primer GGAAGGTTCATCTCCCCAGT 26826..26807
Taqman-P1 FCoV qPCR fluorescent probe
FAM-AATGGCCACACAGGGA
26781..26802
CAACGC-BHQ-1
F614 Forward pyrosequencing primer
GCHCARTATTAYAATGGCAT
23436..23460
AATGG
R766 Biotinylated reverse pyrosequencing primer
BIO-AAGYCTRGCYTGYACT
23588..23568
TGCAT
S680 Pyrosequencing primer
ACAGCCTCDTTAATAGGVGG
23502..23524
ATG
C4 Positive control oligonucleotide
GTAAAGCCRTAGGAGATCGA
Primer does not target
FCoV sequence
Primer does not target
FCoV sequence
CATGTAGTTACACTGATGAG
TCGATCTCC
1Accession number DQ010921.
2Accession number DQ848678.
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The pyrosequencing workstation was prepared with
trays containing wash buffer (10 mM Tris-OAc pH 7.6),
denaturing buffer (0.2 M NaOH), 70% ethanol and distilled
water. The streptavidin bead bound PCR product was taken
up using a vacuum pump and the pyrosequencing bead
collector. The bead collector was then placed in the
70% ethanol for 5 s, in the denaturing buffer for 5 s and in
the wash buffer for 10 s. After turning off the vacuum, the
bead collector was placed in the pyrosequencing plate and
agitated for 30 s to dislodge the beads. The pyrosequenc-
ing plate was heated on a plate holder at 80 °C for 2 min,
before being placed into the PyroMark Q24 (Qiagen) and
left to cool for 5 min.
While the plate was cooling, the pyrosequencing cart-
ridge was prepared. PyroMark Gold Q24 enzyme, substrate
and dNTPs (Qiagen) were added into the appropriate
wells of the cartridge. Volumes were as outlined by the
PyroMark Q24 software. During the experimental set up,
the dispensation order of the nucleotides was defined
as; CGCTCATG. The cartridge was placed into the
PyroMark Q24 instrument and the protocol run.
All primers used in the pyrosequencing assay were
designed using a combination of PyroMark assay design
software (Qiagen), Primer 3’ software [23] and MFold [24],
and were made by Eurofins (MWG Operon) (Table 1).
The primer positions were based on those used by Chang
et al. [13], and numbered according to the FCoV C1Je
genome [GenBank:DQ848678]. Degeneracies were added
to the primers, and the location of the primers optimised,
based upon a sequence alignment comprised of all avail-
able type I FCoV genomes (data not shown).
Sanger sequencing
Conventional PCR to amplify a 153 base-pair DNA frag-
ment encompassing position 1060 in the S protein gene
was carried out as described above, (see pyrosequencing
methods) on samples that did not show a M1058L sub-
stitution in the pyrosequencing assay. The PCR primers
(F614/R766) were then used as sequencing primers in a
standard Sanger sequencing protocol (Eurofins, MWG
Operon).
Statistical analysis
The FCoV relative copy numbers were entered into a
database (Excel 2010, Microsoft) and exported into IBM
SPSS Statistics software (version 19.0). The data sets were
evaluated for normal distribution using the Kolmogorov–
Smirnov (K-S) test. Non-normally distributed data were
described as median and range (minimum and maximum
values). Data evaluating FCoV relative copy numbers in
tissue and faecal samples from cats with and without FIP
were analysed using a multilevel modelling approach
(MLwiN v2.27) [25], to account for the repeated measures
within cats, and a non-parametric Mann-Whitney U test.
The conclusions drawn from both analyses were in full
agreement, so the simpler Mann-Whitney U test ana-
lysis is presented here. Relative copy numbers were
compared between the FIP and non-FIP samples for tissue
and faecal samples combined, for faecal samples only, and
for tissue samples only. Significance was assigned at a level
of P < 0.05.
Ethic statement
Historical samples were collected with full informed con-
sent from owners that samples could be used for research
purposes. The project has been approved under ethical
review by the University of Bristol Animal Welfare and
Ethical Review Board (VIN/14/013).
Results
A total of 112 samples were analysed and full details of
the samples and results are shown in Table 2. In cats with
FIP, the diagnosis was confirmed by histopathology and
the demonstration of FCoV antigen within macrophages in
FIP lesions by IHC. In cats without FIP, the diagnosis was
made by histology; neoplasia (e.g. lymphoma, astrocytoma,
chemodectoma, or biliary cystadenoma), and inflammatory
processes (e.g. chronic lymphoplasmacytic infiltrates of
unknown aetiology in liver and kidney, and broncho-
pneumonia) predominated.
Quantitative RT-PCR
A total of 26 faecal samples were analysed by FCoV qRT-
PCR, and 19 (73%) were positive. These comprised 13 of
16 (81%) faecal samples from cats with FIP, and 6 of 10
(60%) faecal samples from cats without FIP (Table 2).
A total of 86 tissue samples were analysed by FCoV
qRT-PCR, and 52 (60%) were positive. These comprised
43 of 45 (95%) tissue samples from cats with FIP, and 9 of
41 (22%) tissue samples from cats without FIP (Table 2).
Relative FCoV RNA copy numbers were not normally
distributed (P < 0.001). The relative copy numbers in pooled
faecal and tissue samples in the FIP group (median; range:
44 347; 0-16 547 217) were significantly higher (U = 241.0,
P < 0.001) than in the non-FIP group (0, 0-10 090). When
only tissue samples were considered, the relative copy
numbers in the FIP group (75 976; 0-16 574 217) were
also significantly higher than those in the non-FIP group
(0; 0-2 146) (U = 72, P < 0.001). Finally, analysis of faecal
samples alone showed that the relative copy numbers in
the FIP group (9 062; 0-11 819 441) were significantly
higher than those in the non-FIP group (34; 0-10 090)
(U = 36.5, P = 0.02).
Pyrosequencing
The 19 faecal and 52 tissue samples with positive qRT-
PCR results were subjected to the pyrosequencing assay.
Of the 19 faecal samples successfully sequenced, 10 were
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Table 2 Ct values of FCoV RNA extracted from clinical samples and the amino acids coded at position 1058 and
position 1060 in the FCoV S protein
Group Cat number Type of sample Ct value Codon at position 1058
Non FIP 33 Tissue 35.8a UUG (Leu)
Noneb Not applicable
Nonec Not applicable
Non FIP 38 Faeces 34.1 AUG (Met)
Tissue Noned Not applicable
Nonee Not applicable
Non FIP 41 Faeces 26.8 AUG (Met)
Tissue Noneb Not applicable
Nonef Not applicable
Non FIP 48 Faeces 34.2 AUG (Met)
Tissue 35.7b UUG (Leu)
35.8a UUG (Leu)
Non FIP 51 Tissue 37.3f UUG (Leu)
Non FIP 52 Faeces None Not applicable
Tissue Noneg Not applicable
Non FIP 54 Faeces None Not applicable
Tissue 37.3h UUG (Leu)
Nonei Not applicable
Noneb Not applicable
Nonej Not applicable
Nonec Not applicable
Noned Not applicable
Non FIP 56 Tissue 35.9b UUG (Leu)
Noned Not applicable
Nonec Not applicable
28.6k AUG (Met)1
Non FIP 57 Faeces None Not applicable
Tissue 31.6l UUG (Leu)
33.4b UUG (Leu)
Nonec Not applicable
Non FIP 59 Faeces 33.6 AUG (Met)
Tissue Noneb Not applicable
Non FIP 60 Faeces 35.6 AUG (Met)/CUG (Leu)
Tissue Noneb Not applicable
Non FIP 63 Tissue Nonem Not applicable
Non FIP 65 Faeces None Not applicable
Tissue Nonel Not applicable
Noneb Not applicable
Non FIP 69 Faeces 26.3 AUG (Met)
Tissue Nonec Not applicable
Noneb Not applicable
Nonel Not applicable
Noned Not applicable
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Table 2 Ct values of FCoV RNA extracted from clinical samples and the amino acids coded at position 1058 and
position 1060 in the FCoV S protein (Continued)
Non FIP 71 Tissue Noneb Not applicable
Nonea Not applicable
Nonej Not applicable
Non FIP 72 Tissue Noneb Not applicable
Nonej Not applicable
Nonel Not applicable
Noned Not applicable
Nonec Not applicable
FIP 26 Tissue 17.1n UUG (Leu)
FIP 27 Tissue 26.2b UUG (Leu)
FIP 28 Faeces 19.3 AUG (Met)
Tissue 25.5b UUG (Leu)
26.9j UUG (Leu)
FIP 30 Tissue 29.3b UUG (Leu)
FIP 31 Faeces 22.7 AUG (Met)
Tissue 22.2f UUG (Leu)
FIP 32 Faeces 21.0 AUG (Met)
Tissue 17.6a UUG (Leu)
19.2l UUG (Leu)
26.2b UUG (Leu)
FIP 34 Tissue 20.4l UUG (Leu)
FIP 35 Tissue 20.5b UUG (Leu)
FIP 36 Tissue 31.1l UUG (Leu)
FIP 37 Faeces 15.8 AUG (Met)
Tissue 16.2o AUG (Met)2
FIP 42 Faeces 19.9 AUG (Met)
Tissue 20.4l UUG (Leu)
21.6b UUG (Leu)
FIP 43 Tissue 24.1a CUG (Leu)
FIP 44 Faeces 30.0 AUG (Met)
Tissue 19.0p UUG (Leu)
FIP 45 Tissue 25.0q UUG (Leu)
27.9r UUG (Leu)
FIP 46 Faeces 34.2 UUG (Leu)
Tissue 31.7l UUG (Leu)
FIP 47 Faeces 33.3 UUG (Leu)
Tissue 19.4s UUG (Leu)
FIP 49 Faeces 30.9 AUG (Met)
Tissue 21.8c UUG (Leu)
FIP 50 Faeces None Not applicable
Tissue 16.1c UUG (Leu)
FIP 53 Faeces 21.9 AUG (Met)
Tissue 15.5o UUG (Leu)
FIP 55 Tissue 17.7c CUG (Leu)
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obtained using the 40 cycle pyrosequencing assay, whereas
9 required the 50 cycle assay. Of the 52 tissue samples
successfully sequenced, 34 were obtained using the
40 cycle pyrosequencing assay, whereas 18 required
the 50 cycle PCR.
Faecal samples positive by qRT-PCR
In 15 of the 19 (79%) faecal samples positive by qRT-PCR,
a methionine (AUG) codon alone was found at position
1058 (Table 2 and Figure 1A). In 3 of the 19 (16%) sam-
ples, a leucine codon (UUG) alone was found at position
1058 (Table 2 and Figure 1B). Additionally, 1 (5%) sample
(cat 60, faeces) showed a mixed population of RNA coding
for either methionine (AUG) or leucine (CUG) at this
position (Table 2 and Figure 1C).
Importantly, methionine and leucine codons were iden-
tified in faecal RNA samples from both cats with and
without FIP (Table 2). Specifically, a methionine codon
was identified in 10 samples from 10 FIP cats, and a
leucine codon was identified in 3 samples from 3 FIP cats.
Overall, a methionine codon was found in the majority
(10/13; 77%) of faecal samples from cats with FIP, but a
significant number had a leucine codon (3/13; 23%).
Similarly, a methionine codon was identified in 6 sam-
ples from 6 cats without FIP (including one mixed infec-
tion), and a leucine codon was identified in 1 sample from
1 cat without FIP (which had the mixed infection). Over-
all, a methionine codon was found in all 6 faecal samples
from cats without FIP, and 1 sample in 1 cat had a leucine
codon (1/6; 17%, which also had a methionine as a mixed
infection).
Tissue samples positive by qRT-PCR
In 47 of the 52 (90%) tissue samples positive by qRT-PCR,
a leucine codon (44 UUG, 3 CUG) alone was found at
position 1058 (Table 2 and Figures 2A and 2B). In the
remaining 5 of the 52 (10%) tissue samples, a methionine
codon (AUG) was found at this position (Table 2 and
Table 2 Ct values of FCoV RNA extracted from clinical samples and the amino acids coded at position 1058 and
position 1060 in the FCoV S protein (Continued)
20.2b CUG (Leu)
FIP 58 Faeces None Not applicable
Tissue Noneb Not applicable
FIP 61 Faeces 23.1 AUG (Met)
Tissue Noneb Not applicable
FIP 62 Tissue 15.3b UUG (Leu)
17.8j UUG (Leu)
18.0a UUG (Leu)
18.9d UUG (Leu)
20.7l UUG (Leu)
30.9c UUG (Leu)
FIP 66 Faeces 25.5 UUG (Leu)
Tissue 16.7j UUG (Leu)
24.7b UUG (Leu)
FIP 67 Faeces 31.6 AUG (Met)
FIP 68 Tissue 31.1t UUG (Leu)
31.3l UUG (Leu)
33.1b UUG (Leu)
34.0j UUG (Leu)
36.9d UUG (Leu)
FIP 70 Faeces None Not applicable
Tissue 23.3b AUG (Met)1
29.3d AUG (Met)1
30.3l AUG (Met)1
31.0j UUG (Leu)
Tissue types are defined by superscripts: aomentum, bliver, ckidney, dlung, estomach, flymph node, gcerebrum, habdominal lymph node, iheart, jspleen, kcolon, lmesenteric
lymph node, mbrain, nmesentery, opleura, ppericardium, qmedulla, rpons, ssmall intestine, tintestine. The amino acid coded at position 1060 in the S protein of FCoV RNA from
tissue samples without the M1058L substitution is defined by the superscripts: 1UCU (Ser) and 2GCU (Ala).
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Figure 2C). No mixed infections were found in tissue
samples.
Importantly, leucine and methionine codons were iden-
tified in RNA from tissue samples from both cats with
and without FIP (Table 2). Specifically, a leucine codon
was identified in 39 samples from 23 FIP cats, and a
methionine codon was identified in 4 samples from 2 FIP
cats. Overall, a leucine codon was found in the majority
(39/43; 91%) of FIP tissue samples, but a significant
number had a methionine codon (4/43; 9%). Similarly,
a leucine codon was identified in 8 samples from 6 cats
without FIP, and a methionine codon was identified in
1 sample from 1 cat without FIP. Overall, a leucine
codon was found in the majority (8/9; 89%) of tissue
samples from cats without FIP, with a minority (1/9;
11%) having a methionine codon. In one specific case
(cat 70), we noted that the sample from one tissue
(spleen) contained a leucine codon, whereas samples
from three other tissues (liver, lung and mesenteric
lymph node) all contained a methionine codon.
Sanger sequencing of substitution S1060A
Conventional RT-PCR amplification products of RNA
from 5 tissue samples that did not contain the M1058L
substitution (from cats 37, 56 and 70) were analysed by
Sanger sequencing for the S1060A substitution. One of
the 5 samples (cat 37, pleura) showed an alanine codon
at position 1060. The remaining four samples (1 from
cat 56 and three from cat 70) all showed a serine codon
at this position (Table 2).
Discussion
The most important finding in this study is that the
M1058L substitution in the FCoV S protein does not
correlate with FIP disease phenotype, as was proposed
by Chang et al. [13]. We reach this conclusion because
of two observations. First, although a leucine codon was
found in the majority (91%) of tissue samples with FIP
lesions, a leucine codon was also found in the majority
(89%) of non-FIP tissue samples. Second, a significant
number (9%) of FIP tissue samples had a methionine
codon at this position. Tissue samples from naturally
FCoV infected cats without FIP have not been previously
A
C
B
S C G CE A T GT C
S C GE A T GT CC
S C GE A T GT CC
0
25
50
75
0
25
50
75
0
25
50
75
100
125
Re
la
tiv
e 
lig
ht
 u
ni
ts
 (a
rbi
tra
ry
)
Figure 1 Representative sequencing pyrograms of codon 1058 in
faecal RNA samples. A: Pyrogram with an ATG (codon =methionine)
sequence at position 1058 from cat 32, faeces. The peaks represent a
sequence of GCTATGGG. B: Pyrogram with a TTG (codon = leucine)
sequence at position 1058 from cat 46, faeces. The peaks represent
a sequence of GCCTTGGG. C: Pyrogram with a mixture of ATG
(codon = methionine) and CTG (codon = leucine) sequences at
position 1058 from cat 60, faeces. The peaks represent a sequence of
GCT(C/A)TGGG; the relative peak heights suggest that the methionine
and leucine encoding RNAs were present in approximately equal
amounts. The horizontal axis shows the nucleotide dispensation order.
E, enzyme-only control; S, substrate-only control. The initial nucleotide
injected (C) is irrelevant to the sequence and provides a baseline.
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Figure 2 Representative sequencing pyrograms of codon 1058
in tissue RNA samples. A: Pyrogram with a TTG (codon = leucine)
sequence at position 1058 from cat 47, small intestine. The peaks
represent a sequence of GCTTTGGG. B: Pyrogram with a CTG
(codon = leucine) sequence at position 1058 from cat 55, liver. The
peaks represent a sequence of GCTCTGGG. C: Pyrogram with an ATG
(codon =methionine) sequence at position 1058 from cat 70, liver.
The peaks represent a sequence of GCCATGGG. The horizontal axis
shows the nucleotide dispensation order. E, enzyme-only control; S,
substrate-only control. The initial nucleotide injected (C) is irrelevant
to the sequence and provides a baseline.
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evaluated and provide an important insight into FCoV
infection in the absence of FIP. We believe that the
M1058L substitution is more likely to be a marker of
systemic FCoV infection, as opposed to a marker of FIP
or the development of disease. As our tissue samples were
collected post-mortem, we cannot exclude the possibility
that the 6 cats without FIP (8 samples, from cats 33, 49,
51, 54, 56 and 57) and the leucine codon at position 1058,
would have gone on to develop FIP if they had not been
euthanized due to other reasons. However, histopatho-
logical changes consistent with FIP were absent in all 6
cats, and IHC did not identify FCoV antigen.
The finding that the majority of tissue samples from
both cats with and without FIP have a leucine codon at
position 1058 does not challenge the idea that systemic
spread of FCoV is an important step in the development
of FIP. Indeed, the latter is supported by the findings of
our study, since FCoV RNA was found in a far greater
proportion of tissue samples with FIP lesions (95%) than
tissue samples from cats without FIP (22%), and, in those
samples that were qRT-PCR positive, significantly higher
FCoV relative copy numbers were found in the FIP
samples, as has been found in a previous study in naturally
infected cats [26]. However, as sampling in our study took
place post-mortem, it could also be argued that the
elevated FCoV levels in FIP tissues were a consequence of
the massive immunological dysregulation that results from
the disease, rather than a contributing factor towards the
development of disease.
Another viewpoint is that the low levels of FCoV RNA
from the tissues of cats without FIP are a result of FCoV
infecting only fully differentiated macrophages and mono-
cytes, among which are tissue-specific macrophages. This
view is supported by our results as IHC, a detection
method of low sensitivity, did not detect FCoV antigen
anywhere in the PCR-positive tissues from cats without
FIP, providing further evidence of low level viral infection
either of tissue macrophages (in persistently infected
animals) or in monocytes that were in vessels in the
respective organ at the time of sampling [27]. These
findings are also in accordance with recent in vivo and
in vitro studies that showed only the virulent form
of FCoV can effectively and sustainably replicate in
monocytes [9,28,29].
The M1058L substitution was not the only S protein
substitution that was proposed by Chang et al. [13] to cor-
relate with the FIP disease phenotype. They also showed
that a second substitution, S1060A, distinguished a further
4% of FIP from non-FIP associated FCoVs. We confirmed
this result in so far as RNA obtained from one of five
tissue samples that did not show the M1058L substitu-
tion showed the S1060A substitution.
We believe that, as was proposed by Chang et al. [13],
changes such as the M1058L and S1060A substitutions,
and potentially others, could be representative of a class
of mutations that influence the fusogenic activity of the
FCoV S protein and, as such, deserve particular attention
with regard to the pathogenesis of FIP [13]. It is note-
worthy that the substitutions identified by Licitra et al.
[15] that are proposed to distinguish between FCoVs from
animals with and without FIP are also suggested to have
an effect upon the fusogenic activity of the S protein.
With regard to faecal samples, our study found that an
unexpectedly high percentage (81%) of faecal samples
from cats with FIP were FCoV qRT-PCR positive and their
relative copy numbers were significantly higher than those
of faecal samples from cats without FIP. Moreover, the
majority (77%) of FCoV RNA sequences in faecal samples
from cats with FIP had a methionine codon at position
1058 in the FCoV S protein gene, suggesting that these
animals were shedding an enteric form of the virus. It
seems reasonable to suggest that these cats were infected
with an enteric, and a systemic, virulent form of FCoV.
Whether one form was derived from the other following
a single infection or whether these cats were infected
twice with different FCoVs cannot be determined. It has
been proposed that the severe immune dysregulation in
cats with end-stage FIP might create an opportunity for
super-infection by enteric FCoV circulating in surrounding
carriers [17]. More interestingly, a smaller but significant
proportion of faecal samples from cats with FIP (23%) pro-
vided FCoV RNA samples that encoded leucine at position
1058. The current model of FIP pathogenesis proposes that
once the enteric form of the virus has mutated to a virulent
form, it is generally no longer horizontally transmitted via
the faeces [12,16]. This view has been challenged [30], and
the current results also suggest that a systemic form of the
virus can be found in the faeces of FIP cats. However, we
accept that this does not mean that excreted virus is
necessarily able to infect further cats by the enteric route,
as has recently been shown in some experimental studies
[16]. Further research is necessary to resolve these issues.
In contrast to the pattern shown by the analysis of faecal
samples from cats with FIP, the analysis of the faecal sam-
ples from cats without FIP seemed more straight-forward.
All “non-FIP” faecal samples that were FCoV qRT-PCR
positive encoded methionine at position 1058, indicative
of infection with the enteric form of the virus. Also, as
found in our study, a shedding proportion of 60% by
cats without FIP is not unexpected [12,31]. An interesting
faecal sample from a cat without FIP (cat 60) showed a
mixed population of RNAs encoding for either methio-
nine or leucine at position 1058. There was no evidence of
FCoV RNA in the single tissue sample taken from cat
60, and, therefore, one interpretation could be that the
M1058L substitution in the faecal sample was a relatively
recent event and the virus had not yet spread systemically.
However, this interpretation has to be considered as
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tentative because we have observed examples of negative
qRT-PCR results in tissue samples from cats that were
clearly FCoV infected due to their FIP grouping; cat 58,
liver; cat 61, liver. As histopathology results and IHC
for these two liver samples showed changes consistent
with FIP, these negative qRT-PCR results are likely to have
arisen due to an absence of FCoV in the particular sam-
ples taken for molecular analysis, as a variable distribution
of FCoV in affected tissues has been reported [18].
Our study importantly also demonstrated that a PCR-
based pyrosequencing [32] approach is a rapid and accurate
method to identify single nucleotide differences at a specific
position within a DNA fragment, or in our case a viral
genome. However, it has some limitations. Some samples
required 50, rather than 40, cycles of PCR amplification
to generate adequate amounts of DNA for sequencing.
This was especially true for PCR products generated from
samples that contained low amounts of viral RNA, e.g.
tissue samples from cats without FIP. There were also
several samples which, despite containing quantities of
viral RNA measurable by qRT-PCR, did not produce
sufficient PCR products for pyrosequencing, even after
50 amplification cycles. These samples were excluded
from the results as they did not contribute any additional
sequence data to the study. However, one explanation
may be that, despite the degeneracy of the primers used
(F614/R766), differences in the viral primer binding
sites may have precluded efficient amplification in these
samples.
In summary, we have used a pyrosequencing assay to
determine the distribution of a specific M1058L substitu-
tion in the S protein of FCoV RNA obtained from a large
number of post-mortem tissue and faecal samples from cats
with and without FIP. Additionally, Sanger sequencing was
used to determine whether the S1060A substitution was
present in tissue samples that did not contain the M1058L
substitution. This represents the first study that compares
similar samples from cats with and without FIP with regard
to the viral phenotype. Our results contribute to a better
understanding of FCoV genomic mutations and how they
may, or may not, be used as markers of the virus pheno-
type. The results also make clear that the relationship
between the viral genotype and the development of FIP is
complex. We are currently using an approach that involves
the deep sequencing of complete FCoV genomes in clinical
samples, in order to throw further light on this relationship.
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